United States Patent 6,521,212 (UT-15) Patent Landscape: Scope of Claims, Claim Construction Targets, and USFTO Risk for Inhaled Benzindene Prostaglandins
US Patent 6,521,212 covers inhaled methods of treatment using benzindene prostaglandins, with a claim center of gravity around UT-15 (and UT-15 delivery as aerosol droplets <10 µm or powder particles <10 µm) for peripheral vascular disease and pulmonary hypertension, plus a select functional limitation that inhalation has no effect on heart rate. The enforceable scope is method-centric (use claims) and is likely to be asserted against any US marketing authorization or clinical program that uses similar inhaled dosage forms and particle size distributions for UT-15.
What is US 6,521,212 really claiming: “inhalation method of use” for UT-15 and benzindene prostaglandins?
Core inventive concept: administer by inhalation a benzindene prostaglandin (specifically UT-15 in dependent claims) to treat peripheral vascular disease or pulmonary hypertension, with additional constraints on aerosol/powder particle size (<10 µm) and optionally sustained release and no heart-rate effect.
Claim set map (independent vs dependent)
| Claim |
Category |
Treated indication |
Drug scope |
Delivery form scope |
Key additional limitations |
| 1 |
Independent |
Peripheral vascular disease |
“a benzindene prostaglandin” |
Inhalation formulation |
Baseline treatment by inhalation |
| 2 |
Dependent |
Peripheral vascular disease |
Benzindene prostaglandin |
Aerosolized |
Aerosol (implied inhalable aerosol) |
| 3 |
Dependent |
Peripheral vascular disease |
UT-15 |
Aerosolized |
UT-15 specifically |
| 4 |
Dependent |
Peripheral vascular disease |
UT-15 |
Aerosol droplets <10 µm |
Droplets with UT-15 in liquid carrier |
| 5 |
Dependent |
Peripheral vascular disease |
UT-15 (via claim dependency) |
Inhalation |
Mammal = human |
| 6 |
Independent |
Pulmonary hypertension |
UT-15 or salt/ester |
Inhalation delivery |
Broader indication than PVD |
| 7 |
Dependent |
Pulmonary hypertension |
UT-15 (via claim dependency) |
Aerosolized |
Aerosolized form |
| 8 |
Dependent |
Pulmonary hypertension |
UT-15 |
Aerosol droplets <10 µm |
Droplets in pharmacologically acceptable liquid carrier |
| 9 |
Dependent |
Pulmonary hypertension |
UT-15 |
Powder form |
Particles <10 µm |
| 10 |
Dependent |
Peripheral vascular disease |
Benzindene prostaglandin |
Inhalation |
Formulation includes sustained release |
| 11 |
Dependent |
Pulmonary hypertension |
UT-15 |
Inhalation |
UT-15 sustained release form |
| 12 |
Dependent |
Peripheral vascular disease (via claim 1) |
Benzindene prostaglandin |
Inhalation |
Inhalation has no effect on heart rate |
Scope compression analysis: what each claim element does
Claim 1: “Peripheral vascular disease” + “inhalation” + “benzindene prostaglandin”
- Indication anchor: must be “peripheral vascular disease” as recited. If a competitor targets a narrower vascular condition not falling under “peripheral vascular disease,” that is a potential noninfringing path.
- Method anchor: “administering … by inhalation” makes this a medical method claim, not a formulation claim per se. But claim breadth still reaches any formulation that is inhaled and contains an eligible active.
- Active ingredient anchor: “benzindene prostaglandin” is a class term. The class breadth depends on the patent’s specification, but on the claim face it covers at least UT-15 and any other benzindene prostaglandin defined in the patent family.
Claims 2-4: “aerosolized” + droplets <10 µm
- These claims add a delivery-system particle size limiter. The “less than 10 micrometers” constraint is a technical boundary that can be engineered around if distribution and measurement method are controlled.
- Claim 4’s “droplets comprising said UT-15 in a suitable … liquid carrier” further ties infringement analysis to a liquid formulation rather than a dry powder.
Claim 6-8: “pulmonary hypertension” + inhaled UT-15 + aerosol droplets <10 µm
- Claim 6 is broad within the pulmonary hypertension use case because it does not require particle size in the independent claim.
- Claim 8 adds “droplets less than 10 µm,” again creating an engineered delivery boundary.
Claim 9: powder route + particles <10 µm
- Claim 9 creates a separate infringement track for a dry powder inhaler-type product using particles under 10 µm. If a competitor uses a powder with broader particle size, they may reduce claim coverage.
Claims 10-11: sustained release
- “Sustained release form” is an additional limitation that can be difficult for a challenger to avoid if the competitor product is designed for prolonged exposure. If “sustained release” is not met as construed, the claims are less likely to read on faster release inhalation products.
Claim 12: “inhalation … has no effect on heart rate”
- This functional limitation is a litigation focal point. It will typically require evidence of clinical or pharmacodynamic outcome: heart-rate effect must be “no effect” under the claim’s implied metric. It can be a high-variance claim, but it also provides a defense lever if a competitor demonstrates measurable heart-rate effects or if “no effect” is not met.
How do these claim limits translate into enforceable infringement theories for competitors?
1) Indication-based infringement
- If a generic or follow-on developer seeks approval for peripheral vascular disease or pulmonary hypertension, the method claims create exposure even when the drug substance is the same. Use-based claims can be implicated by labeling and prescribing intent.
- If the competitor’s label targets other indications, the method claims may be less directly implicated.
2) Route and delivery device exposure
- The claims require inhalation. That includes aerosols and powders as specified in dependent claims.
- Delivery particle size creates a technical infringement lever:
- Aerosol droplets <10 µm (claims 4 and 8)
- Powder particles <10 µm (claim 9)
3) Formulation architecture exposure
- Sustained release claims (10 and 11) create additional exposure if the inhaled product is designed as controlled release.
4) Functional pharmacology exposure
- “No effect on heart rate” (claim 12) is both a litigation risk and a possible engineering target.
What patent estate surrounds US 6,521,212: continuation and blocking issues
You provided the claims but not the patent metadata (filing date, assignee, application number, or patent number family members). Without those data, an accurate, complete landscape for other US-family patents, continuation chains, related device patents, and terminal disclaimer status cannot be produced to the required standard.
As a result, the analysis below focuses strictly on what can be derived from the claim set scope you provided, and on how those claim features typically map to parallel patent coverage in US practice.
Typical adjacent protection areas (high-probability in this claim family type)
- Compound/chemical class claims: benzindene prostaglandin, UT-15, salts/esters.
- Formulation claims: inhalable liquid formulations, aerosol generation technologies, excipient packages, and particle engineering.
- Device claims: nebulizer/DPIs with particle size control.
- Manufacturing methods: producing sustained release inhalable formulations with controlled release profiles.
- Clinical method claims: additional endpoints in PVD and pulmonary hypertension, dosing regimens, or patient selection criteria.
Those are the patent categories that frequently surround method-of-use inhalation claims, but enumerating specific US patents by number and claim language requires record-level data that is not present in your prompt.
Claim construction hotspots likely to drive validity and infringement outcomes
“benzindene prostaglandin”
- Expect disputes over whether “benzindene prostaglandin” covers only the specific compounds disclosed as benzindene prostaglandins in the specification, or a broader genus based on structural features.
- If UT-15 is the commercial lead, UT-15’s structural definition is a core marker for claim coverage and for novelty/obviousness challenges.
“inhalation”
- Inhalation is commonly argued to include any administration intended to reach the lungs. If a competitor argues for local delivery elsewhere (upper airway vs lower lung), the scope turns on claim construction and how “treating pulmonary hypertension” anchors the intended location of action.
“aerosolized form” and “droplets less than 10 micrometers”
- Infringement will hinge on measured aerosol droplet size distribution (e.g., mass median aerodynamic diameter vs geometric mean vs any “less than 10 µm” interpretation).
- A competitor may attempt to show that their emitted aerosol has a distribution where a meaningful portion is ≥10 µm, or that the effective fraction reaching the lung does not meet the limitation as construed.
“powder form comprising particles less than 10 micrometers”
- For powder, particle size is subject to DPI engineering and agglomeration. The legal question is whether claim scope reads on the pre-inhalation powder distribution or on delivered particle size after dispersion.
“sustained release”
- Expect disputes over what qualifies as “sustained release” under the specification and claims. A competitor may pursue a release profile that is not “sustained” as interpreted, or argue that the claim requires a particular release mechanism.
“no effect on heart rate”
- This is an outcome-based limitation. In practice it becomes a trial question with clinical data.
- If the competitor’s product causes any statistically or clinically relevant heart-rate change, it can weaken “no effect” compliance.
How would US 6,521,212 affect FTO for inhaled UT-15 development?
High-risk zones
- Any inhaled UT-15 program in the US with label indication matching:
- peripheral vascular disease
- pulmonary hypertension
- Products intended to emit/ deliver:
- aerosol droplets <10 µm (liquid)
- powder particles <10 µm (dry powder)
- Products marketed as sustained release inhaled UT-15.
Lower-risk zones (relative, based on your claim set)
- Programs targeting other indications outside the literal phrase “peripheral vascular disease” and “pulmonary hypertension.”
- Delivery platforms intentionally designed to avoid the <10 µm constraint.
- Formulations that are clearly not sustained release.
- If a competitor demonstrates heart-rate changes, claim 12 becomes harder to satisfy by plaintiffs, though it does not avoid claims 1-11.
How do these claims compare across indications: PVD vs pulmonary hypertension?
| Feature |
Claims for PVD |
Claims for pulmonary hypertension |
| Independent indication anchor |
Claim 1 |
Claim 6 |
| UT-15 specificity |
Dependent (claim 3) |
Independent (claim 6) |
| Aerosol droplet size |
Dependent (claim 4) |
Dependent (claim 8) |
| Powder size track |
Not stated |
Dependent (claim 9) |
| Sustained release |
Dependent (claim 10) |
Dependent (claim 11) |
| Heart-rate functional limit |
Present (claim 12) |
Not stated |
Practical effect: pulmonary hypertension creates direct exposure through claim 6 for inhaled UT-15 (including salts/esters) even without particle-size limitations, with additional particle-size and sustained-release dependencies.
Key takeaways on claim breadth and litigation leverage
- US 6,521,212 is a method-of-treatment patent that is strongly tethered to inhaled delivery and two specific disease areas.
- The claim architecture provides multiple infringement “hooks”:
- broad inhaled UT-15 use for pulmonary hypertension (claim 6)
- narrowed droplet/particle size limits (<10 µm) (claims 4, 8, 9)
- sustained release variants (claims 10, 11)
- a functional pharmacology limiter tied to heart rate (claim 12)
- The most engineerable infringement perimeter is the <10 µm limitation, with the most data-dependent limiter being “no effect on heart rate.”
Key Takeaways
- US 6,521,212 covers inhaled methods using benzindene prostaglandins, with UT-15 as the specific target in multiple dependent and one independent claim for pulmonary hypertension.
- Claims 4, 8, and 9 create particle-size boundaries (<10 µm) for aerosol droplets (liquid) and powder particles (dry powder).
- Claims 10 and 11 add sustained-release constraints that can be engineered but require defensible release-profile evidence.
- Claim 12 is a functional outcome claim requiring evidence that inhalation has no effect on heart rate.
FAQs
1) Does US 6,521,212 require UT-15 for peripheral vascular disease treatment?
No. Claim 1 covers any benzindene prostaglandin for PVD by inhalation; UT-15 specificity is introduced in dependent claims.
2) What particle size thresholds are asserted in the inhaled dosage claims?
The dependent claims require aerosol droplets less than 10 micrometers (claims 4 and 8) and powder particles less than 10 micrometers (claim 9).
3) Is sustained release required to infringe?
No for claims 1 and 6. Sustained release is only in dependent claims 10 and 11.
4) Can a product avoid infringement by using a different inhalation format?
Changing between liquid aerosol vs dry powder does not avoid coverage by itself; it shifts the claim set into either droplet-size limitations or powder-size limitations.
5) What is the practical meaning of “no effect on heart rate” in claim 12?
It is an outcome limitation tied to heart-rate pharmacodynamics, requiring clinical or pharmacodynamic evidence to satisfy or refute.
References
- United States Patent 6,521,212. (Claims as provided in prompt).
